LogicBio Therapeutics, Inc. (LOGC): Price and Financial Metrics
LogicBio Therapeutics, Inc. (LOGC)
Today's Latest Price: $7.00 USD
Updated Sep 25 4:00pm
Add LOGC to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
LOGC Stock Summary
- LOGC's went public 1.94 years ago, making it older than just 3.68% of listed US stocks we're tracking.
- LOGC's price/sales ratio is 83.33; that's higher than the P/S ratio of 96.98% of US stocks.
- Revenue growth over the past 12 months for LogicBio Therapeutics Inc comes in at 94.52%, a number that bests 94.47% of the US stocks we're tracking.
- Stocks that are quantitatively similar to LOGC, based on their financial statements, market capitalization, and price volatility, are ARCT, EVGN, ETTX, SYBX, and CDTX.
- Visit LOGC's SEC page to see the company's official filings. To visit the company's web site, go to www.logicbio.com.
LOGC Stock Price Chart Technical Analysis Charts
LOGC Price/Volume Stats
| Current price | $7.00 | 52-week high | $11.60 |
| Prev. close | $7.00 | 52-week low | $3.05 |
| Day low | $6.92 | Volume | 648,141 |
| Day high | $7.75 | Avg. volume | 78,053 |
| 50-day MA | $7.47 | Dividend yield | N/A |
| 200-day MA | $7.31 | Market Cap | 165.49M |
LogicBio Therapeutics, Inc. (LOGC) Company Bio
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.
Loading social stream, please wait...